Lee Se-Hoon et al. found that B. bifidum was significantly enriched among the fecal microbes in NSCLC treatment responders in a study of patients treated with different methods, and it was found in an animal model that supplementation with B. bif_K57 combined with oxaliplatin or anti-PD-1 antibody significantly enhanced the antitumor effect. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.